Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Tancini

Showing results (131-140 of 218) with videos related to

Pageof 22
Sort By:
Tumori|August 31, 1993
Immunoendocrine therapy with interleukin-2 (IL-2) and medroxyprogesterone acetate (MPA): a randomized study with or without MPA in metastatic renal cancer patients during IL-2 maintenance treatment after response or stable disease to IL-2 subcutaneous therapyP Lissoni, S Barni, G Tancini, et al.
Tumori|June 30, 1991
Mitoxantrone as a single agent in pretreated metastatic breast cancer: effects on T lymphocyte subsets and their relation to clinical responseS Barni, P Lissoni, F Paolorossi, et al.
Tumori|August 31, 1994
Lymphocytosis decline is not responsible for tumor progression in cancer patients chronically treated with interleukin-2P Lissoni, S Barni, M Andres, et al.
Oncology|January 1, 1994
Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinomaP Lissoni, S Barni, A Ardizzoia, et al.
The European Journal of Surgery = Acta Chirurgica|January 1, 1993
Effects of a preoperative course of interleukin-2 on surgical and immunobiological variables in patients with colorectal cancer: a phase 2 studyF Brivio, P Lissoni, S Barni, et al.
Tumori|June 30, 1988
Melatonin increase as predictor for tumor objective response to chemotherapy in advanced cancer patientsP Lissoni, G Tancini, S Barni, et al.
Tumori|June 30, 1994
Serum levels of insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactinS Barni, P Lissoni, F Brivio, et al.
Tumori|August 31, 1986
Prolactin response to thyrotropin-releasing hormone in early and advanced human breast cancerS Barni, P Lissoni, G Tancini, et al.
Oncology|November 1, 1995
Prediction of recurrence in operable breast cancer by postoperative changes in prolactin secretionP Lissoni, S Barni, M Cazzaniga, et al.
Anticancer Research|May 1, 1990
Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancerP Lissoni, S Barni, C Archili, et al.
Pageof 22

Showing results (131-140 of 218) with videos related to

Sort By:
Pageof 22
Tumori|August 31, 1993
Immunoendocrine therapy with interleukin-2 (IL-2) and medroxyprogesterone acetate (MPA): a randomized study with or without MPA in metastatic renal cancer patients during IL-2 maintenance treatment after response or stable disease to IL-2 subcutaneous therapyP Lissoni, S Barni, G Tancini, et al.
Tumori|June 30, 1991
Mitoxantrone as a single agent in pretreated metastatic breast cancer: effects on T lymphocyte subsets and their relation to clinical responseS Barni, P Lissoni, F Paolorossi, et al.
Tumori|August 31, 1994
Lymphocytosis decline is not responsible for tumor progression in cancer patients chronically treated with interleukin-2P Lissoni, S Barni, M Andres, et al.
Oncology|January 1, 1994
Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinomaP Lissoni, S Barni, A Ardizzoia, et al.
The European Journal of Surgery = Acta Chirurgica|January 1, 1993
Effects of a preoperative course of interleukin-2 on surgical and immunobiological variables in patients with colorectal cancer: a phase 2 studyF Brivio, P Lissoni, S Barni, et al.
Tumori|June 30, 1988
Melatonin increase as predictor for tumor objective response to chemotherapy in advanced cancer patientsP Lissoni, G Tancini, S Barni, et al.
Tumori|June 30, 1994
Serum levels of insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactinS Barni, P Lissoni, F Brivio, et al.
Tumori|August 31, 1986
Prolactin response to thyrotropin-releasing hormone in early and advanced human breast cancerS Barni, P Lissoni, G Tancini, et al.
Oncology|November 1, 1995
Prediction of recurrence in operable breast cancer by postoperative changes in prolactin secretionP Lissoni, S Barni, M Cazzaniga, et al.
Anticancer Research|May 1, 1990
Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancerP Lissoni, S Barni, C Archili, et al.
Pageof 22